. Author manuscript; available in PMC: 2013 Aug 12.

Published in final edited form as: Cancer. 2010 Nov 15;116(22):5251–5260. doi: 10.1002/cncr.25487

Table 1.

Eligible Studies

Study	Disease After Primary Therapy	Treatment Regimens	No.	Median PFS	Median OS
Consolidation
Alberts 2006⁶	No pathologic evidence of disease (pCR)	lnterferon-a every week, 6 weeks	35	47 months	NR at 147 months
Alberts 2006⁶	No pathologic evidence of disease (pCR)	Observation	35	94 months	87 months
Barakat 1998²⁷	pCR	Intraperitoneal cisplatin plus etopo side every 28 days, 3 cycles	36	NR, 61 % at 36 months	NA
Barakat 1998²⁷	pCR	Observation	46	28.5 months	NA
Ben-Baruch 1994²⁸ Menczer 1989²⁹	pCR or clinical CR	Intraperitoneal cisplatin every 28 days, 3 cycles	19	36 months	60 months
Ben-Baruch 1994²⁸ Menczer 1989²⁹	pCR or clinical CR	Radiotherapy	18	23 months	39 months
Bolis 2006³⁰	pCR or CR prior to second Look	Epidoxorubicin, every 21 days, 4 Cycles	64	NA	57.8% alive at 5 years
Bolis 2006³⁰	pCR or CR prior to second Look	No treatment	74	NA	54.5% alive at 5 years
Bruzzone 1990³¹	CR or SD	Continuation of initial front-line ther apy regimen, 3 courses	21	NR, 71.5% NED at 22 months	48 months
Bruzzone 1990³¹	CR or SD	Radiotherapy	20	16 months	24 months
De Placido 2004⁸	CR or PR	Topotecan, Days 1–5 every 3 weeks, 4Cycles	137	18.2 months	NA
De Placido 2004⁸	CR or PR	Observation	136	28.4 months	NA
Goldberg 2001³²	CR	Abdominal irradiation	60	NA	30 months
Goldberg 2001³²	CR	No treatment	79	NA	41 months
Goldhirsch 1988³³	pCR	Whole abdominal radiotherapy	24	NR, 83% NED at 3 years	NA
Goldhirsch 1988³³	pCR	Any other treatment	21	29.2 months	NA
Gori 2005³⁴	CR	Intraperitoneal cisplatin plus Hyperthermia	29	NA, 3.1% NED at 5 years	64.4 months
Gori 2005³⁴	CR	No treatment	19	NA, 3.7% NED at 5 years	46.4 months
Lambert 1993³⁵	Residual disease <2 cm	Carboplatin, 5 cycles	59	NR, 76% NED at 5 years	46 months
Lambert 1993³⁵	Residual disease <2 cm	Whole abdominal radiotherapy	58	NR, 76% NED at 5 years	49 months
Lee 2006³⁶	CR	Paclitaxel plus cisplatin, 3 cycles	42	25 months	74.3 months
Lee 2006³⁶	CR	Observation	39	26 months	78 months
Menczer 1992³⁷	CR	Intraperitoneal cisplatin every 28 days, 3 cycles	25	NA	69.3 months
Menczer 1992³⁷	CR	No additional treatment	12	NA	45.7 months
Nicholson 1998³⁸	pCR (experimental); pCR or CR (controls)	Intraperitoneal radioimmunotherapy, HMFG1 labeled with yttrium-90	25	NA	94 months
Nicholson 1998³⁸	pCR (experimental); pCR or CR (controls)	No radioimmunotherapy	20	NA	60 months
Nicoletto 2004³⁹	pCR	5-FU (for 5 days), followed by cispla tin (Day 6 or 7), every 28 days, 3 Cycles	61	68 months	87 months
Nicoletto 2004³⁹	pCR	No treatment	61	73 months	89 months
Oei 2007⁴⁰; Verheijen 2006⁴¹	No macroscopic disease at second look	Intraperitoneal radioimmunotherapy, HMFG1 labeled with yttrium-90	224	Mean, 64 months	NR, 68.7% alive at 3.5 years
Oei 2007⁴⁰; Verheijen 2006⁴¹	No macroscopic disease at second look	Standard treatment	223	Mean, 67 months	NR, 72.6% alive at 3.5 years
Papadimitriou 2008⁴²	CR	Cyclophosphamide plus melphalan	37	7.1 years	96 months
Papadimitriou 2008⁴²	CR	Observation	43	1.5 years	73.2 months
Piccart 2003⁴³	pCR	Intraperitoneal cisplatin every 3 weeks, 4 cycles	76	64 months	117 months
Piccart 2003⁴³	pCR	Observation	76	40 months	87 months
Pickel 1999⁴⁴; Pickel 1991⁴⁵	NED	Whole abdominal radiotherapy	32	76 months	NR at 104 months
Pickel 1999⁴⁴; Pickel 1991⁴⁵	NED	No radiotherapy	32	26 months	40 months
Sorbe 2003⁴⁶’⁴⁷ (consolidation vs control)	pCR	Abdominal radiotherapy	32	116 months	120 months
Sorbe 2003⁴⁶’⁴⁷ (consolidation vs control)	pCR	No treatment	31	32 months	70.6 months
Varia 2003⁴⁸	pCR	Intraperitoneal radioactive Phosphorus	104	43.3 months	84 months
Varia 2003⁴⁸	pCR	No treatment	98	32.9 months	73 months
Maintenance
Berek 2009⁴⁹; Berek 2004⁵⁰ Berek 2008⁵¹	NED	Oregovomab every 4 weeks, 3 cycles, followed by every 12 weeks, up to 2 years	73	13.3 months	57.5 months
Berek 2009⁴⁹; Berek 2004⁵⁰ Berek 2008⁵¹	NED	Placebo	72	10.3 months	48.6 months
Hall 2004⁵²; Hall, unpublished data	NED	lnterferon-a-2a, 3 days every weeks	89	14.4 months	49 months
Hall 2004⁵²; Hall, unpublished data	NED	Observation	95	15.9 months	38 months
Hirte 2006⁵³	NED, CR, and PR (residual dis ease <2 cm)	Tanomastat	122	10.4 months	13.9 months
Hirte 2006⁵³	NED, CR, and PR (residual dis ease <2 cm)	Placebo	121	9.2 months	11.8 months
Lawton 1990⁵⁴	<2 cm residual disease	Chlorambucil every days, 14 days every 28 days, 12 cycles	25		20.6 months
Lawton 1990⁵⁴	<2 cm residual disease	Total abdominal and pelvic radiotherapy	25		15.5 months
Markman 2003⁷; Markman 2009¹³	CR	Paclitaxel every 28 days, 12 cycles	150	22 months	53 months
Markman 2003⁷; Markman 2009¹³	CR	Paclitaxel every 28 days, 3 cycles	146	14 months	48 months
Micha 2006¹⁴; Micha 2009⁵⁵; Micha 2005⁵⁶	CR	Paclitaxel every 21 days, 3 cycles	13	11 months	38 months
Micha 2006¹⁴; Micha 2009⁵⁵; Micha 2005⁵⁶	CR	Paclitaxel every 21 days, 12 cycles	13	24 months	NR
Pecorelli 2009¹⁵	pCR, CR	Paclitaxel every 21 days, 6 cycles	101	34 months	77 months
Pecorelli 2009¹⁵	pCR, CR	Observation	99	30 months	84 months
Sorbe 2003⁴⁶’⁴⁷ (maintenance vs control)	pCR	Carboplatin plus doxorubicin or epirubicin, 6 cycles	35	37 months	78 months
Sorbe 2003⁴⁶’⁴⁷ (maintenance vs control)	pCR	No treatment	31	32 months	70.6 months
Umesaki 1999⁵⁷	pCRorCA 125 <8 U/mL	Cisplatin every day for 5 days, every 3–4 months, 3–5 years	15	NA	79.3 months
Umesaki 1999⁵⁷	pCRorCA 125 <8 U/mL	No treatment or <1 year of study treatment	10	NA	67.4 months

PFS indicates progression-free survival; OS, overall survival; pCR, pathologic complete response; NR, not reached; NA, not available; CR, complete response; SD, stable disease; NED, no evidence of disease; PR, partial response; HMFG1, human milk fat globulin 1; 5-FU, 5-fluorouracil.